Clinical Trial Update: SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of SHR-A1811 for HER2-positive breast cancer with suboptimal neoadjuvant response, which is currently not y…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• SHR-A1811

Snippet

Sponsor: Chuan Wang | Conditions: Early Breast Cancer, HER2 + Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING